Oncolytics Biotech Inc Stock Price, News & Analysis

Oncolytics Biotech (NASDAQ: ONCY) hosted a key opinion leader (KOL) webinar focusing on pelareorep's clinical data in pancreatic and gastrointestinal cancers. The event highlighted significant survival benefits demonstrated by pelareorep-based combinations in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) patients.

Key findings show that pelareorep combined with chemotherapy represents a promising treatment option for mPDAC patients. Translational data from multiple clinical trials validated pelareorep's mechanism of action, demonstrating tumor replication, chemokine expression stimulation, and correlation between tumor-infiltrating lymphocytes expansion and tumor size reduction.

Oncolytics Biotech (NASDAQ: ONCY), a clinical-stage immunotherapy oncology company, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received formal confirmation from Nasdaq's Listing Qualifications Department on July 22, 2025.

After falling below the required $1.00 minimum bid price in February 2025, ONCY has maintained a closing bid price at or above $1.00 for 10 consecutive business days from July 8 through July 21, 2025. The company is now fully compliant with all Nasdaq listing standards and will continue trading on the Nasdaq Capital Market.

Oncolytics Biotech (NASDAQ: ONCY) presented comprehensive translational data demonstrating the effectiveness of its immunotherapy candidate pelareorep across multiple tumor types. The data, derived from the GOBLET and AWARE-1 studies, showed consistent immune activation signatures in pancreatic, gastrointestinal, and breast cancers.

Key findings revealed that pelareorep successfully converts 'cold' tumors to 'hot' by upregulating interferons and PD-L1, expanding tumor-infiltrating lymphocytes, and modifying the tumor microenvironment. The company expects additional translational data readouts next year and plans to provide an updated clinical timeline by the end of Q3 2025.

Oncolytics Biotech (NASDAQ: ONCY) has announced a Key Opinion Leader (KOL) webinar scheduled for July 22, 2025, at 1:00 p.m. ET. The event will focus on the company's pelareorep therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC) and gastrointestinal cancers.

The webinar will feature distinguished experts including Dr. Dirk Arnold, Dr. Alexander Eggermont, Dr. Sanjay Goel, and Dr. Devalingam Mahalingam, who will join Oncolytics' management team. They will discuss existing clinical data and explore pelareorep's potential as an immunotherapy treatment. The event will include a formal presentation, roundtable discussion, and a live Q&A session.

Oncolytics Biotech (NASDAQ: ONCY) has announced transformative survival data for its immunotherapy drug pelareorep across multiple tumor types. The company reported a significant two-year survival benefit of 21.9% vs. 9.2% in pancreatic cancer (mPDAC) studies. In HR+/HER2- metastatic breast cancer trials, pelareorep demonstrated a median overall survival benefit exceeding 10 months compared to standard chemotherapy.

Key clinical achievements include a 62% objective response rate in mPDAC when combined with chemotherapy and checkpoint inhibitors. The drug's safety profile has been validated across more than 1,100 patients, showing manageable side effects. Pelareorep holds Fast Track designations for both metastatic breast cancer and mPDAC, along with Orphan Drug Designations for pancreatic cancer from both FDA and EMA.

Oncolytics Biotech (NASDAQ: ONCY) has appointed Andrew Aromando as Chief Business Officer, a strategic hire bringing over 30 years of life sciences industry experience. Aromando, who most recently served as Chief Operating Officer at Ambrx Biopharma, played a key role in the company's $2 billion acquisition by Johnson & Johnson.

In his new role, Aromando will lead global business development and contribute to corporate, clinical, and regulatory strategies. A key focus will be optimizing the value of pelareorep's clinical data across multiple tumor types, including pancreatic, breast, and anal cancers. The company has accumulated clinical evidence from over 1,100 patients.

As part of his compensation package, Aromando received a stock option grant for 750,000 shares at CAD$0.93, vesting over three years, and 500,000 restricted stock units that vest upon specific transaction conditions related to company acquisition or pelareorep licensing.

Oncolytics Biotech (NASDAQ: ONCY) has appointed Jared Kelly as its new CEO and Board member. Kelly, who recently helped orchestrate Ambrx Biopharma's $2B sale to Johnson & Johnson, brings expertise in transformative deals and corporate strategy. The company's lead drug pelareorep, an immunotherapeutic agent with FDA Fast Track designation, has shown promising results in multiple cancers. In metastatic pancreatic cancer trials, it achieved >60% objective response rate, with 2-year survival rates 4-6 times higher than controls. The drug has also demonstrated efficacy in metastatic breast cancer and anal canal cancer trials. Kelly received significant equity incentives, including 2.85M stock options at CAD$0.57 vesting over three years, 1.9M performance-based options, and restricted stock units tied to potential acquisition or licensing deals.

Oncolytics Biotech (NASDAQ: ONCY) presented new data from its Phase I/II GOBLET clinical trial at the 2025 ASCO Annual Meeting, demonstrating the effectiveness of its immunotherapy drug pelareorep in treating pancreatic ductal adenocarcinoma (PDAC). The study revealed pelareorep's mechanism of action, showing how it stimulates multiple immune responses and converts immunologically cold tumors into active ones.

Key findings include pelareorep's ability to expand reovirus-specific T cells and increase cytokines and chemokines that enable anti-tumor immune responses. The GOBLET Cohort 1 trial, which evaluated pelareorep in combination with nab-paclitaxel, gemcitabine, and atezolizumab, demonstrated impressive results with a 62% overall response rate, 85% disease control rate, and 45% 12-month survival rate in first-line metastatic PDAC patients.

Oncolytics Biotech (NASDAQ: ONCY) reported its Q1 2025 financial results and clinical progress. The company's lead drug pelareorep showed promising results across multiple cancer types. Key highlights include a 33% objective response rate in anal carcinoma patients and positive safety data in pancreatic cancer trials. The company reported $15.3 million in cash and equivalents, with a net loss of $6.7 million ($0.08 per share) compared to $6.9 million ($0.09 per share) in Q1 2024. R&D expenses decreased to $4.1 million from $5.7 million year-over-year. Oncolytics secured a US$20 million share purchase agreement with Alumni Capital LP to support ongoing clinical development.